Application based on results from the TROPION-Breast01 Phase III trial
Additional BLA under review in the US for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for patients with advanced nonsquamous non-small cell lung cancer
https://finance.yahoo.com/news/datopotamab-deruxtecan-biologics-license-application-110000638.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.